Share on Pinterest Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Shelby Knowles/Bloomberg/Getty Images Zepbound outperformed ...

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials. OSA is a prevalent ...

Lack of insurance coverage and high costs remain a barrier to obtaining tirzepatide. Eli Lilly’s weight loss drug Zepbound outperformed competitor Novo Nordisk’s Wegovy, according to a ...

The SURMOUNT-5 trial, published over the weekend in the New England Journal of Medicine and presented at the European Congress on Obesity, showed that treatment with tirzepatide (Zepbound; Eli Lilly) ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

Mounjaro ® KwikPen ® is a multi-dose single-patient-use prefilled pen. Each Mounjaro ® KwikPen ® contains four fixed doses of 0.6 mL, each dose taken once weekly. 2 It is available in six different ...

Eli Lilly, the company that produces tirzepatide, sponsored the study, which was conducted at 32 sites across the United States and Puerto Rico. All participants received counseling regarding diet and ...

more physicians and patients are witnessing significant weight reduction beyond what they have seen before," Aronne said in a statement released by tirzepatide-maker Eli Lilly. "The SURMOUNT-5 ...

People taking Eli Lilly and Co.’s obesity drug ... Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, while those who ...